Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: To provide a device and a method for strengthening a cornea or a sclera or suppressing a progression of a disease in a non-invasive manner, enabling treatment in daily life without treatment in a confined state at a medical institution for a fixed period of time and without ablation of the corneal epithelium as in conventional corneal crosslinking. The above-described problem is solved by a non-invasive cornea and sclera strengthening device that irradiates violet light toward an eye administered with an administration agent used to strengthen a corneal tissue or a scleral tissue, and is configured so that an irradiance of the violet light onto a surface of the eye is within a range of 0.1 to 1 mW/cm2, and a time of irradiation of the violet light onto the eye is within a range of one to five hours per day.

Abstract: A device for supporting diagnosis has: a reception unit that is configured to receive a fundus image of a subject eye; an identification unit provided with a trained model that is configured to recognize, in the fundus image of the subject eye, an area of abnormality in blood circulation, wherein the model has been trained based upon an image of a fundus and an area of abnormality in blood circulation specified in a fluorescent angiography image of the fundus; and an output unit that is configured to output information relating to the area of abnormality in blood circulation recognized in the fundus image of the subject eye.

Abstract: Using the medium of the present invention for inducing a cornea endothelial substitute cell from an iPS cell, the medium containing an insulin-like growth factor and a STAT3 activator, and not containing a basic fibroblast growth factor or a ROCK inhibitor, and the method of the present invention for inducing corneal endothelial substitute cells from iPS cells by using the medium, it becomes possible to efficiently produce corneal endothelial substitute cells, particularly to efficiently produce corneal endothelial substitute cells from iPS cells. Furthermore, it becomes possible to stably produce large amounts of corneal endothelial substitute cells by inducing differentiation of iPS cells into corneal endothelial substitute cells more efficiently.

Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400Ak×Tk)/(?k=more than 315400Ak) T315 nm or less=(?k=300315Ak×Tk)/(?k=300315Ak).

Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Abstract: To provide a spraying device and a spraying method for moisture mist that supply at least a micro liquid to the eye, and can be used for dry eye symptom relief, drug delivery, allergy prevention, relaxation, and the like. The above-described problem is solved by a spraying device (1, 31) that supplies at least a micro liquid, and includes a spraying element (16) that sprays a mist-like substance containing the micro liquid onto a local region (50). The raw material is a liquid raw material or a solid raw material that may include a medicinal additive. The medicinal additive is preferably selected from among menthol, analgesics, antibiotics, antiallergic agents, steroids, intraocular pressure-lowering agents, and the like. The spraying device (1, 31) may be an eyeglasses-type spraying device (1) in which the local region (50) is configured by a rim (3) and a temple (6) of eyeglasses, or a cup-type spraying device (31) in which the local region (50) includes an opening (32).

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3).At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6).

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3). At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6).

Abstract: A lottery device includes: a drawing body having medium entrance units which are provided along a circumferential direction thereof, and into each of which a game medium can enter; a driving mechanism driving the drawing body in the circumferential direction; a dividing device dividing a periphery of a path of the medium entrance units, in which path the medium entrance units travel, into lottery segments in the circumferential direction; a medium introduction mechanism introducing the game medium individually into each lottery segment; an entrance unit detection device detecting a medium entrance unit into which the game medium has entered; a displacement amount detection device detecting an amount of displacement in the circumferential direction; and a lottery segment distinguishing device distinguishing from which of the lottery segments the game medium has entered into the medium entrance unit based on a result of detection by the displacement amount detection device.

Abstract: The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Abstract: Novel HIF inhibitors having low cytotoxicity and suitable for ophthalmologic treatment and agents for the treatment or prevention of ischemic diseases, glaucoma, optic nerve diseases, retinal degenerative diseases, retinal degenerative diseases, angiogenic retinal diseases, cancer, neurodegenerative or autoimmune diseases are provided. The present invention is a therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative disease, or autoimmune disease, which comprises as an active ingredient one or more or an extract thereof selected from the group consisting of plants belonging to the genus Asian, plants belonging to the genus Swiss, plants belonging to the genus Grape, plants belonging to the genus Brassica, fish belonging to the genus Kivinago, and so on.

Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Abstract: Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing graft-versus-host disease comprises administering a phenylbutyric acid or a pharmacologically acceptable salt thereof to a patient in need of treatment or prevention of graft-versus-host disease. It is preferable that the graft-versus-host disease be a graft-versus-host disease that manifests after bone marrow transplantation. It is preferable that the graft-versus-host disease be ocular graft-versus-host disease.

Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.